271 related articles for article (PubMed ID: 26387540)
1. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
2. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
3. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
[TBL] [Abstract][Full Text] [Related]
4. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
5. BRN2 and MITF together impact AXL expression in melanoma.
Simmons JL; Neuendorf HM; Boyle GM
Exp Dermatol; 2022 Jan; 31(1):89-93. PubMed ID: 33119145
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
Boyle GM; Woods SL; Bonazzi VF; Stark MS; Hacker E; Aoude LG; Dutton-Regester K; Cook AL; Sturm RA; Hayward NK
Pigment Cell Melanoma Res; 2011 Jun; 24(3):525-37. PubMed ID: 21435193
[TBL] [Abstract][Full Text] [Related]
7. Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens.
Kholmanskikh O; van Baren N; Brasseur F; Ottaviani S; Vanacker J; Arts N; van der Bruggen P; Coulie P; De Plaen E
Int J Cancer; 2010 Oct; 127(7):1625-36. PubMed ID: 20099279
[TBL] [Abstract][Full Text] [Related]
8. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
9. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.
Riesenberg S; Groetchen A; Siddaway R; Bald T; Reinhardt J; Smorra D; Kohlmeyer J; Renn M; Phung B; Aymans P; Schmidt T; Hornung V; Davidson I; Goding CR; Jönsson G; Landsberg J; Tüting T; Hölzel M
Nat Commun; 2015 Nov; 6():8755. PubMed ID: 26530832
[TBL] [Abstract][Full Text] [Related]
10. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
11. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
Goodall J; Carreira S; Denat L; Kobi D; Davidson I; Nuciforo P; Sturm RA; Larue L; Goding CR
Cancer Res; 2008 Oct; 68(19):7788-94. PubMed ID: 18829533
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
Vachtenheim J; Ondrušová L
Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
[TBL] [Abstract][Full Text] [Related]
13. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.
He S; Li CG; Slobbe L; Glover A; Marshall E; Baguley BC; Eccles MR
Melanoma Res; 2011 Feb; 21(1):24-34. PubMed ID: 21164369
[TBL] [Abstract][Full Text] [Related]
14. NFATc2 is a potential therapeutic target in human melanoma.
Perotti V; Baldassari P; Bersani I; Molla A; Vegetti C; Tassi E; Dal Col J; Dolcetti R; Anichini A; Mortarini R
J Invest Dermatol; 2012 Nov; 132(11):2652-60. PubMed ID: 22718120
[TBL] [Abstract][Full Text] [Related]
15. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene.
Kobi D; Steunou AL; Dembélé D; Legras S; Larue L; Nieto L; Davidson I
Pigment Cell Melanoma Res; 2010 Jun; 23(3):404-18. PubMed ID: 20337985
[TBL] [Abstract][Full Text] [Related]
17. microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.
Arts N; Cané S; Hennequart M; Lamy J; Bommer G; Van den Eynde B; De Plaen E
PLoS One; 2015; 10(4):e0122517. PubMed ID: 25853464
[TBL] [Abstract][Full Text] [Related]
18. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
Du J; Miller AJ; Widlund HR; Horstmann MA; Ramaswamy S; Fisher DE
Am J Pathol; 2003 Jul; 163(1):333-43. PubMed ID: 12819038
[TBL] [Abstract][Full Text] [Related]
19. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.
Thurber AE; Douglas G; Sturm EC; Zabierowski SE; Smit DJ; Ramakrishnan SN; Hacker E; Leonard JH; Herlyn M; Sturm RA
Oncogene; 2011 Jul; 30(27):3036-48. PubMed ID: 21358674
[TBL] [Abstract][Full Text] [Related]
20. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
